With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. The pharmaceuticals sector is pivotal in the development, manufacturing, and distribution of drugs and ...

While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana.

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. The pharmaceuticals ...

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ sits at a Zacks Rank #2 (Buy), holds a Value Style Score of A, and ...

The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Needham on April 10, 2025. The analyst firm set a price target for $210.00 expecting JAZZ to rise to within 12 months ...

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.